ClinicalTrials.gg
Not yet recruitingNCT07889193Updated Oct 22, 2026

Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)

A Phase 1 interventional study of Cell-based Trivalent Split Influenza Virus Vaccine (cTIV) and Egg-based Trivalent Split Influenza Virus Vaccine (eTIV) in Seasonal Influenza, sponsored by Sinovac Biotech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1, Interventional, and Prevention

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Influenza, Human · Sinovac Biotech Co., Ltd.

Planned enrollment
18th of 25
175 · median 400
Started
2026
with 1 other
Phase 1
4 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 27th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 6 Months and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac Biotech Co., Ltd., in participants aged 6 months and above.

Read the detailed description

A total of 175 healthy trial participants ≥6 months of age will be enrolled, including 50 children aged 6-35 months, 25 children aged 3-8 years, 50 children and adults aged 9-59 years, and 50 elderly participants aged ≥60 years. All trial participants will be randomized in a 2:2:1 ratio to the investigational group, active comparator group or placebo group. Children aged 6-35 months vaccine-naïve children aged 3-8 years will receive 2 doses of cell-based trivalent influenza vaccine (cTIV), egg-based trivalent influenza vaccine (eTIV), or placebo, with an interval of 28 days. Other trial participants will receive a single dose of investigational vaccine cTIV, eTIV, or placebo.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy trial participants aged ≥6 months;

    Among them, for children aged 3-8 years:

    • Influenza vaccine-naïve: children who have never received any influenza vaccine (licensed or );
    • Previously vaccinated: children who have received at least 1 dose of influenza vaccine (licensed or investigational);
  2. The trial participant and/or the participant's legal representative can understand and voluntarily sign the form;
  3. Willing and able to comply with all visit schedules, sample collection, vaccination and other trial procedures, and maintain contact at all times during the trial;
  4. Able to provide legal identification documents.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any licensed or influenza vaccine within the previous 18 months, or intention to receive any other influenza vaccine during the study;
  2. Clinically or laboratory-confirmed influenza infection within the previous 6 months;
  3. Known history of a severe allergic reaction to the study vaccine or any of its components, including urticaria, dyspnea, angioedema, or anaphylaxis;
  4. Fever on the scheduled day of study vaccination, defined as an axillary temperature >37.0°C before vaccination;
  5. Skin lesions, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with vaccination or the assessment of local reactions;
  6. laboratory abnormalities outside the reference ranges in any of the following parameters:

    • Hematology: white blood cell count, , or count; Serum biochemistry: (ALT), aspartate aminotransferase (AST), or total ; Urinalysis: urine protein;
  7. Severe congenital malformations or genetic disorders, including but not limited to Down syndrome or phenylketonuria;
  8. Poorly controlled chronic disease or a history of serious disease, including but not limited to cardiovascular disease, metabolic disease (e.g., poorly controlled diabetes mellitus), hematologic disease, hepatic or renal disease, gastrointestinal disease, respiratory disease, , or a history of major organ transplantation. For participants aged ≥18 years, hypertension inadequately controlled with medication is defined as: Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg for participants aged 18-59 years; Systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg for participants aged ≥60 years;
  9. disease, immunodeficiency disorder, or a relevant family history, including but not limited to Guillain-Barré syndrome (GBS), systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, anatomic asplenia, functional asplenia, or infection;
  10. Coagulation abnormalities, including coagulation factor deficiency or platelet disorders;
  11. Current or previous severe neurologic disease, including epilepsy, convulsions, or seizures, except for a history of febrile seizures in infants or young children; severe psychiatric disorder; or a family history of schizophrenia;
  12. Receipt of agents or other immunomodulatory therapy for ≥14 days within the previous 6 months, including prednisone at a dose of ≥20 mg/day or ≥2 mg/kg/day, or another systemic at an equivalent prednisone dose; receipt of cytotoxic therapy; or intention to receive any such therapy during the study. Topical and inhaled corticosteroids are excluded;
  13. Receipt of immunoglobulins or other blood products within the previous 3 months, or intention to receive such products during the study;
  14. Receipt of any other investigational drug or vaccine within the previous 30 days, or intention to receive any such drug or vaccine during the study;
  15. Receipt of a or viral vector vaccine within the previous 14 days, or receipt of a subunit, inactivated, or other non-live vaccine within the previous 7 days;
  16. Any acute illness or acute exacerbation of a chronic disease within the previous 7 days, or any known or suspected active infection;
  17. Breastfeeding or pregnancy, including a positive urine pregnancy test, or an intention to become pregnant or donate oocytes from the time of signing the form until 6 months after study vaccine administration; for male participants, an intention to father a child or donate sperm during the same period;
  18. Any other condition that, in the investigator's judgment, would make the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    Investigational Group :Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)

    Children aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose

    Biological: Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)

  • Active comparator
    Active Comparator Group: Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)

    Children aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose

    Biological: Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)

  • Placebo comparator
    Placebo Group: Placebo

    Children aged 6-35 months and vaccine-naïve children aged 3-8 years: 2 doses administered 28 days apart. All other participants: 1 single dose

    Other: Placebo

Interventions

  • BiologicalCell-based Trivalent Split Influenza Virus Vaccine (cTIV)

    Investigational trivalent split influenza virus vaccine produced in MDCK cells, administered intramuscularly.

  • BiologicalEgg-based Trivalent Split Influenza Virus Vaccine (eTIV)

    Licensed trivalent split influenza virus vaccine (Anflu) produced in embryonated chicken eggs, administered intramuscularly.

  • OtherPlacebo

    0.9% normal saline for intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions from Day 0 to Day 28 after each dose

    Time frame: 0-28 days after each dose

Secondary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions from Day 0 to Day 7 after each dose

    Time frame: 0-7 days after each dose

  2. Incidence of serious adverse events(SAEs)

    Incidence of SAEs from the first dose up to 6 months after the last dose

    Time frame: From the first dose up to 6 months after the last dose

  3. Incidence of abnormal and clinically significant hematology, serum biochemistry and urinalysis parameters on Day 3 after vaccination

    Incidence of laboratory abnormalities with clinical significance in hematology, serum biochemistry and urinalysis collected on Day 3 post-vaccination among trial participants.

    Time frame: Day 3 after vaccination

  4. The geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after completion of full vaccination.

    GMT for each vaccine-related influenza strain, assessed at Day 28 after full vaccination.

    Time frame: Day 28 after completion of full vaccination

  5. The geometric mean increase (GMI) of HI antibodies against each antigen 28 days after full vaccination.

    GMI for each vaccine-related influenza strain, assessed at Day 28 after full vaccination.

    Time frame: Day 28 after full vaccination

  6. The seroconversion rates of HI antibodies against each antigen 28 days after full vaccination.

    Seroconversion rate for each vaccine-related influenza strain, assessed at Day 28 after full vaccination.

    Time frame: Day 28 after full vaccination

  7. The seroprotection rates of antibodies against each antigen 28 days after full vaccination.

    Seroprotection rate (HI titer ≥1:40) for each vaccine-related influenza strain, assessed at Day 28 after full vaccination.

    Time frame: Day 28 after completion of full vaccination

07

Study locations

1 site
  • Guangdong Provincial Center for Disease Control and Prevention (Guangdong Academy of Preventive Medical Sciences)
    Guangzhou, Guangdong, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 2 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Oct 22, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07889193
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Liao Yuyi
Contact
727771666@qq.com
15914307772
Liao Yuyi
principal investigator · Guangdong Provincial Center for Disease Control and Prevention (Guangdong Academy of Preventive Medical Sciences)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion